Trials / Completed
CompletedNCT02216890
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-CD70A | Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks) |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2017-02-15
- Completion
- 2017-02-15
- First posted
- 2014-08-15
- Last updated
- 2018-04-19
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02216890. Inclusion in this directory is not an endorsement.